

References

I-260

1. Ghassan K, Chan S, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. *J Clin Oncol*. 2022;40(4):379.
2. Johnson M, Cho B, Luft A, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. *J Clin Oncol*. 2022;JCO2200975.
3. Tremelimumab-actl In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated November 29, 2022.
4. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Tremelimumab.
5. Micromedex DrugDex Compendium®. 2024. Tremelimumab-actl.
6. Imjudo® (tremelimumab-actl) injection, for intravenous use [package insert]. AstraZeneca Pharmaceuticals LP. Wilmington, DE. Revised 06/2023.
7. National Comprehensive Cancer Network (NCCN). Tremelimumab-actl. NCCN Drugs and Biologics Compendium®. 2024.